Overview of high-risk Food and Drug Administration recalls for cosmetics and personal care products from 2002 to 2016

被引:7
|
作者
Janetos, Timothy M. [1 ]
Akintilo, Lisa [2 ]
Xu, Shuai [2 ]
机构
[1] Northwestern Univ, Dept Ophthalmol, McGaw Med Ctr, Chicago, IL 60611 USA
[2] Northwestern Univ, McGaw Med Ctr, Dept Dermatol, Chicago, IL 60611 USA
关键词
cosmetic recalls; cosmetic safety; Food and Drug Administration; moisturizers; personal care products; sunscreens; UNIT;
D O I
10.1111/jocd.12824
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: There have been several recent controversies surrounding cosmetic products that have impacted health. Dermatologists are often the first to encounter these issues, and recalls are one metric of a safety profile of cosmetics and their impact on health. Objective: To analyze all recalls of cosmetic and personal care products from 2002 to 2016. Methods: This observational study describes all FDA cosmetic and personal care product recalls, acquired via a Freedom of Information Act request, from 2002 to 2016. The total number of Class I, Class II, and Class III recalls, number and origin of manufacturers, number of products affected, and main reason for recall were collected. Results: A total of 14 Class I, 266 Class II, and 33 Class III recalls were recorded. Baby products comprised the largest product category accounting for 24% of all recalls (76/313). 76% of recalls were due to bacterial contamination (237/313), followed by unapproved components, labeling issues, and skin irritation. The 14 Class I recalls accounted for 1.9 million products in distribution. Conclusions: Cosmetic recalls impacted millions of products and had the potential to cause serious harm. Dermatologists have the ability to strengthen public safety by reporting adverse events, encouraging recalls of harmful products, and lobbying through dermatology organizations for meaningful change to current cosmetic regulation.
引用
收藏
页码:1361 / 1365
页数:5
相关论文
共 35 条
  • [21] Assessment of Clinical Trial Evidence for High-Risk Cardiovascular Devices Approved Under the Food and Drug Administration Priority Review Program
    Jones, L. Camille
    Dhruva, Sanket S.
    Redberg, Rita F.
    JAMA INTERNAL MEDICINE, 2018, 178 (10) : 1418 - 1420
  • [22] US Food and Drug Administration-Mandated Postmarketing Studies for High-risk Cardiovascular Devices Approved 2015-2019
    Hidano, Danelle
    Dhruva, Sanket S.
    Redberg, Rita F.
    JAMA INTERNAL MEDICINE, 2022, 182 (05) : 556 - 558
  • [23] Inclusion of Demographic-Specific Information in Studies Supporting US Food & Drug Administration Approval of High-Risk Medical Devices
    Dhruva, Sanket S.
    Mazure, Carolyn M.
    Ross, Joseph S.
    Redberg, Rita F.
    JAMA INTERNAL MEDICINE, 2017, 177 (09) : 1390 - 1391
  • [24] The US Food and Drug Administration 515 Program Initiative Addressing the Evidence Gap for Widely Used, High-Risk Cardiovascular Devices?
    Rathi, Vinay K.
    Kesselheim, Aaron S.
    Ross, Joseph S.
    JAMA CARDIOLOGY, 2016, 1 (02) : 117 - 118
  • [25] Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014
    Rathi, Vinay K.
    Wang, Bo
    Ross, Joseph S.
    Downing, Nicholas S.
    Kesselheim, Aaron S.
    Gray, Stacey T.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2017, 156 (02) : 285 - 288
  • [26] Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011
    Rathi, Vinay K.
    Krumholz, Harlan M.
    Masoudi, Frederick A.
    Ross, Joseph S.
    JAMA NETWORK OPEN, 2020, 3 (08)
  • [27] US Food and Drug Administration-Mandated Postmarketing Studies for High-risk Cardiovascular Devices Approved 2015-2019 Reply
    Kadakia, Kushal T.
    Ross, Joseph S.
    Krumholz, Harlan M.
    JAMA INTERNAL MEDICINE, 2022,
  • [28] Overview of the 2012 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting on the Edwards SAPIEN transcatheter heart valve for high-risk aortic stenosis patients
    Barbash, Israel M.
    Dvir, Danny
    Waksman, Ron
    AMERICAN HEART JOURNAL, 2013, 165 (05) : 710 - 715
  • [29] Prophylactic Administration of Tranexamic Acid Reduces Blood Products' Transfusion and Intensive Care Admission in Women Undergoing High-Risk Cesarean Sections
    Binyamin, Yair
    Frenkel, Amit
    Gruzman, Igor
    Lerman, Sofia
    Bichovsky, Yoav
    Zlotnik, Alexander
    Stav, Michael Y.
    Erez, Offer
    Orbach-Zinger, Sharon
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (16)
  • [30] Evaluation of the US Food and Drug Administration validated method for detection of Cyclospora cayetanensis in high-risk fresh produce matrices and a method modification for a prepared dish
    Almeria, Sonia
    da Silva, Alexandre J.
    Blessington, Tyann
    Cloyd, Tami Craig
    Cinar, Hediye Nese
    Durigan, Mauricio
    Murphy, Helen R.
    FOOD MICROBIOLOGY, 2018, 76 : 497 - 503